- 執筆（排名不分先后）陳樹達［中山大學附屬第七醫院（深圳）］，呂瑞娟（首都醫科大學附屬北京天壇醫院），徐馨（重慶醫科大學附屬第一醫院）;
中國抗癲癇協會,
Email: lmzhou56@163.com
Citation： 中國抗癲癇協會, 中國抗癲癇協會藥物治療專業委員會. 拉考沙胺治療癲癇的中國專家共識. Journal of Epilepsy, 2026, 12(1): 1-13. doi: 10.7507/2096-0247.202512006 Copy
Copyright ? the editorial department of Journal of Epilepsy of West China Medical Publisher. All rights reserved
| 1. | |
| 2. | |
| 3. | |
| 4. | |
| 5. | |
| 6. | |
| 7. | |
| 8. | |
| 9. | |
| 10. | |
| 11. | |
| 12. | |
| 13. | |
| 14. | |
| 15. | |
| 16. | |
| 17. | |
| 18. | |
| 19. | |
| 20. | |
| 21. | |
| 22. | |
| 23. | |
| 24. | |
| 25. | |
| 26. | |
| 27. | |
| 28. | |
| 29. | |
| 30. | |
| 31. | |
| 32. | |
| 33. | 中國抗癲癇協會. 臨床診療指南: 癲癇病分冊(2023修訂版). 北京: 人民出版社, 2023 . |
| 34. | SIGN. A national clinical guideline: Epilepsies in children and young people: Investigative procedures and management. 2021. |
| 35. | |
| 36. | |
| 37. | |
| 38. | |
| 39. | |
| 40. | |
| 41. | |
| 42. | |
| 43. | |
| 44. | |
| 45. | |
| 46. | |
| 47. | |
| 48. | |
| 49. | |
| 50. | |
| 51. | |
| 52. | |
| 53. | |
| 54. | |
| 55. | |
| 56. | |
| 57. | |
| 58. | |
| 59. | |
| 60. | |
| 61. | |
| 62. | |
| 63. | |
| 64. | |
| 65. | |
| 66. | |
| 67. | |
| 68. | |
| 69. | |
| 70. | |
| 71. | |
| 72. | |
| 73. | |
| 74. | |
| 75. | |
| 76. | |
| 77. | |
| 78. | |
| 79. | |
| 80. | |
| 81. | |
| 82. | |
| 83. | |
| 84. | |
| 85. | Biton V, Gil-Nagel A, Isojarvi J, et al. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav, 2015, 52(Pt A): 119-127. |
| 86. | |
| 87. | |
| 88. | |
| 89. | |
| 90. | |
| 91. | |
| 92. | |
| 93. | |
| 94. | |
| 95. | |
| 96. | |
| 97. | |
| 98. | |
| 99. | |
| 100. |
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33. 中國抗癲癇協會. 臨床診療指南: 癲癇病分冊(2023修訂版). 北京: 人民出版社, 2023 .
- 34. SIGN. A national clinical guideline: Epilepsies in children and young people: Investigative procedures and management. 2021.
- 35.
- 36.
- 37.
- 38.
- 39.
- 40.
- 41.
- 42.
- 43.
- 44.
- 45.
- 46.
- 47.
- 48.
- 49.
- 50.
- 51.
- 52.
- 53.
- 54.
- 55.
- 56.
- 57.
- 58.
- 59.
- 60.
- 61.
- 62.
- 63.
- 64.
- 65.
- 66.
- 67.
- 68.
- 69.
- 70.
- 71.
- 72.
- 73.
- 74.
- 75.
- 76.
- 77.
- 78.
- 79.
- 80.
- 81.
- 82.
- 83.
- 84.
- 85. Biton V, Gil-Nagel A, Isojarvi J, et al. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav, 2015, 52(Pt A): 119-127.
- 86.
- 87.
- 88.
- 89.
- 90.
- 91.
- 92.
- 93.
- 94.
- 95.
- 96.
- 97.
- 98.
- 99.
- 100.
-
Previous Article
Cover -
Next Article
Low-dose lacosamide for children with primary paroxysmal kinesigenic dyskinesia: efficacy analysis